|
|
| Maladies Respiratoires > Etude de marché sectorielle |
| Commercial Insight: Herpes and Respiratory Antivirals - Leaders Rise and Fall |
|
|
|
|
€ 9 690,00 |
Editeur
: |
Datamonitor |
Langue
: |
Anglais |
Date de publication : |
Octobre 2005 |
Taille du document : |
218 |
Autres informations : |
Description , Table des matières |
| |
|
|
|
|
| |
|
Rechercher d'autres rapports et études à commander
Rechercher et commander ici parmi 50.000 études de marché publiées par les principaux instituts d'études internationaux
|
| Rapports privés en relation |
|
The Global Diabetes Market: Therapeutics, Diagnostics and Complications
218 pages | Août 2006 |
Diabetes is one of the largest therapeutic segments of global pharmaceutical sales and during the last 10 years it has grown by a compound average growth rate of nearly 20% from around US$4 billion in |
1 999,20 €
|
| |
| |
US State Market Index: Cold remedies
12 pages | Juillet 2006 |
The metrics in this report cover three year trends in Cold remedies [Manufacturing sector], broken out on a state-by-state basis.
Analysis is based on data applied from 2 industry firms.
Industr |
475,00 €
|
| |
| |
OTC Cough and Cold Remedies in France
10 pages | Juin 2005 |
Euromonitor International’s ‘OTC Cough and Cold Remedies in France' Major Market Profile report offers an introduction to the market.
It is c.
10 pages long and provides a top line overview of |
198,00 €
|
| |
| |
Partneringreview 2006 Vol 2 Ch 7: Respiratory (PR06V2C07)
112 pages | Février 2006 |
Partneringreview 2006 – Therapy area Respiratory provides an in depth view into the respiratory disease focused deals and alliances announced in 2005, in a clear and accessible format.
The report |
795,00 €
|
| |
| |
US Cough Drops & Throat Lozenges 2005
12 pages | Juin 2005 |
Snapdata's US Cough Drops & Throat Lozenges 2005 report provides 2004 year-end market data, with 2005 estimates and five-year forecasts.
The report gives an instant overview of the US cough drop an |
240,00 €
|
| |
| |
US Cough Syrup 2004
12 pages | Juillet 2004 |
Snapdata's US Cough Syrup 2004 report provides 2003 year-end market data, with 2004 estimates and five-year forecasts.
The report gives an instant overview of the US cough syrup market, and covers |
240,00 €
|
| |
| |
Activity Holidays
154 pages | Février 2006 |
This Market Assessment report covers the market for activity holidays, which are defined to include a wide variety of events that involve some form of physical exertion, ranging from rambling and fish |
1 260,00 €
|
| |
| |
Travel and Tourism Canada
36 pages | Février 2005 |
About this report2003 was a grim year for the tourism industry worldwide but Canada was particularly afflicted by the downturn in travel.
As well as external factors such as the Iraq war, which cur |
445,00 €
|
| |
| |
US Cough Syrup 2005
13 pages | Juin 2005 |
Snapdata's US Cough Syrup 2005 report provides 2004 year-end market data, with 2005 estimates and five-year forecasts.
The report gives an instant overview of the US cough syrup market, and covers |
240,00 €
|
| |
| |
OTC Cough and Cold Remedies in the United Kingdom
10 pages | Juin 2005 |
Euromonitor International’s ‘OTC Cough and Cold Remedies in the UK' Major Market Profile report offers an introduction to the market.
It is c.
10 pages long and provides a top line overview of |
198,00 €
|
| |
| |
|
| |
| Autres secteurs en relation |
|
|
|
| |
|
| |
| |
| Présentation de l'étude de marché - Description & Table des matières |
|
| Commercial Insight: Herpes and Respiratory Antivirals - Leaders Rise and Fall |
|
|
Introduction
Within the herpes and respiratory antiviral subcategory HSV/VZV products have been key growth drivers, accounting for 77% of a market worth $2,190m in 2004. Despite lost of US branded Valtrex in 2009, the continued uptake of flu and post-transplant CMV antivirals along with the anticipated launch of first-in-class RSV antiviral, A-60444 will to some extent offset revenue loss by 2014.
Scope
Market overview by geographical area and disease indication, with value analysis of clinical and commercial factors underlying product performance
Assessment of country-specific drivers and resistors likely to impact the herpes and respiratory antiviral market
Case study analysis of the key players in the market and further the success of follow-up products Valtrex for HSV/VZV and Valcyte for CMV
Future market outlook per disease indication and individual products taking into account key market events in particular, patent expiries
Highlights
The anti-infective vaccine market is poised for explosive growth, leading to a shift of R&D focus from antiviral therapy to preventative vaccination and hence a dwindling herpes and respiratory antiviral pipeline. However, clinical unmet needs mainly in CMV, VZV related post-herpetic neuralgia (PHN) and RSV maintain the call for new products.
Capitalizing on the Zovirax legacy, a large number of indication expansions and effective marketing strategies by ID leader GSK, sales of follow-up product Valtrex have experienced accelerated growth. In 2004, Valtrex achieved blockbuster status, selling $1,090m in the seven major markets.
Currently available RSV therapies are sub-optimal and expensive, being reserved for 'at risk' immunocompromised patient groups such as neonates. With successful development and positioning of first-in-class RSV small molecule inhibitor A-60444, Arrow/Novartis could establish a new treatment paradigm in RSV.
Reasons to Purchase
Identify key environmental opportunities and threats that will impact the use and uptake of new and existing products
Select effective lifecycle management strategies through best-in-class case study analysis of key players in the market
Understand and capitalize on clinical unmet needs in the market, either through lifecycle management of marketed drugs or new product development
|
|
Introduction
Within the herpes and respiratory antiviral subcategory HSV/VZV products have been key growth drivers, accounting for 77% of a market worth $2,190m in 2004. Despite lost of US branded Valtrex in 2009, the continued uptake of flu and post-transplant CMV antivirals along with the anticipated launch of first-in-class RSV antiviral, A-60444 will to some extent offset revenue loss by 2014.
Scope
Market overview by geographical area and disease indication, with value analysis of clinical and commercial factors underlying product performance
Assessment of country-specific drivers and resistors likely to impact the herpes and respiratory antiviral market
Case study analysis of the key players in the market and further the success of follow-up products Valtrex for HSV/VZV and Valcyte for CMV
Future market outlook per disease indication and individual products taking into account key market events in particular, patent expiries
Highlights
The anti-infective vaccine market is poised for explosive growth, leading to a shift of R&D focus from antiviral therapy to preventative vaccination and hence a dwindling herpes and respiratory antiviral pipeline. However, clinical unmet needs mainly in CMV, VZV related post-herpetic neuralgia (PHN) and RSV maintain the call for new products.
Capitalizing on the Zovirax legacy, a large number of indication expansions and effective marketing strategies by ID leader GSK, sales of follow-up product Valtrex have experienced accelerated growth. In 2004, Valtrex achieved blockbuster status, selling $1,090m in the seven major markets.
Currently available RSV therapies are sub-optimal and expensive, being reserved for 'at risk' immunocompromised patient groups such as neonates. With successful development and positioning of first-in-class RSV small molecule inhibitor A-60444, Arrow/Novartis could establish a new treatment paradigm in RSV.
Reasons to Purchase
Identify key environmental opportunities and threats that will impact the use and uptake of new and existing products
Select effective lifecycle management strategies through best-in-class case study analysis of key players in the market
Understand and capitalize on clinical unmet needs in the market, either through lifecycle management of marketed drugs or new product development
|
|
|
PPLSEN
|
|
|
|
|
